



**CORAL LABORATORIES LTD**

ISO 9001:2008 Certificate No. IN015692

### 1.3.1 Summary of Product Characteristics (SmPC)

---

**PRODUCT : JASETHER 225 MG INJECTION**

**( $\alpha$  –  $\beta$  Arteether Injection 225 mg/3 ml)**

**MODULE I : ADMINISTRATIVE INFORMATION**

**COUNTRY : NIGERIA**





**CORAL LABORATORIES LTD**

ISO 9001:2008 Certificate No. IN015692

**1. Name of the medicinal product:**

JASETHER 225 MG INJECTION

**1.1 Name of the medicinal product:**

$\alpha - \beta$  Arteether Injection 225 mg/3 ml

**1.2 Strength:**

Each ml contains:

$\alpha - \beta$  Arteether 75 mg

Arachis Oil BP q.s.

**1.3 Pharmaceutical form:**

Injection

**2. Qualitative and quantitative composition**

**Qualitative declaration:**

Each ml contains:

$\alpha - \beta$  Arteether 75 mg

**Quantitative declaration:**

Each ml contains:

$\alpha - \beta$  Arteether 75 mg

Arachis Oil BP q.s.

**3. Pharmaceutical form**

Injection

**4. Clinical particulars:**

**4.1 Therapeutic indications:**

Severe malaria including cerebral malaria and as a second line drug in chloroquine resistant malaria cases only.

---

**PRODUCT : JASETHER 225 MG INJECTION**

**( $\alpha - \beta$  Arteether Injection 225 mg/3 ml)**

**MODULE I : ADMINISTRATIVE INFORMATION**

**COUNTRY : NIGERIA**





#### **4.2 Posology and method of administration**

$\alpha$ - $\beta$  Arteether Injection is for intramuscular use only.

Adult: 150 mg for 3 consecutive days

Children - 3mg/Kg per day administered by intramuscular injection over a 3-day period

The injection must be given under aseptic conditions, deep intramuscularly in the upper lateral quadrant of the buttock.

No other drug should be mixed in the same syringe.

#### **4.3 Contraindications**

JASETHER 225 MG INJECTION is contraindicated in patients hypersensitive to artemisinin derivatives or any of the excipients.

#### **4.4 Special warnings and precautions for use**

When treating children, particular care should be taken to ensure the correct doses are given and retained.

#### **4.5 Interaction with other medicinal products and other forms of interaction**

Prolonged QT interval has been reported in some studies with high dosage of artemisinin derivatives. The cardiac effects of artemisinins are not very important from a clinical point of view, except that caution should be exercised against combinations with other drugs that prolong the QT interval, such as quinine and halofantrine.

#### **4.6 Pregnancy and lactation**

Pregnancy

Adequate studies regarding safe use of artemisinin derivatives during pregnancy are not available. Artemisinin derivatives should not be used in pregnancy as primary drugs for uncomplicated malaria cases but these can be used for treatment of severe or complicated p. Falciparum malaria infection in patients of multiple drug resistance, if the benefits justify the potential risk to the fetus.

---

**PRODUCT : JASETHER 225 MG INJECTION**

**( $\alpha$  –  $\beta$  Arteether Injection 225 mg/3 ml)**

**MODULE I : ADMINISTRATIVE INFORMATION**

**COUNTRY : NIGERIA**





Nursing Mother It is not known whether  $\alpha$ - $\beta$  Arteether is secreted in human milk. Because many drugs are secreted in human milk caution should be exercised while using  $\alpha$ - $\beta$  Arteether.

**4.7 Effects on ability to drive and use machines:**

Not Known.

**4.8 Undesirable effects:**

While neurotoxicity has been reported in experimental animals, there is no evidence of neurotoxicity in human beings with artemisinin derivatives.  $\alpha$ - $\beta$  Arteether is usually well tolerated. However, nausea, dizziness and depressed GIT activity can occur. Clinical, neurological, electrocardiographic and biochemical monitoring did not reveal significant toxicity. Apart from some increase in eosinophil numbers, no haematological abnormality was seen.

**4.9 Overdose:**

Overdose treatment should be symptomatic and supportive.

**5. Pharmacological properties:**

**5.1 Pharmacodynamics properties:**

Pharmacotherapeutic group: Antimalarial

ATC code: P01BE

Mechanism of action

$\alpha$ - $\beta$  Arteether is a fast acting blood schizonticidal agent for *P. falciparum* malaria at the erythrocytic stage.  $\alpha$ - $\beta$  Arteether is concentrated in parasitized erythrocytes. The functional group responsible for antimalarial activity of  $\alpha$ - $\beta$  Arteether is endoperoxide bridge. Iron from the digested haemoglobin of the parasite's victim reduces this bridge, releasing a highly reactive free radical iron species which causes lysis of the parasitic cell. It is also proposed that  $\alpha$ - $\beta$  Arteether inhibits the protein synthesis and alters the ribosomal organization and endoplasmic reticulum.



---

**PRODUCT : JASETHER 225 MG INJECTION**

**( $\alpha$  –  $\beta$  Arteether Injection 225 mg/3 ml)**

**MODULE I : ADMINISTRATIVE INFORMATION**

**COUNTRY : NIGERIA**



## **5.2 Pharmacokinetic Properties**

$\alpha$ - $\beta$  Arteether is transformed into dihydroartemisinin. It has a half life of 20 hours. It is eliminated by hepatic metabolism. The elimination is much slower compared to other artemisinin compounds.

## **5.3 Preclinical safety data**

No intolerance has yet been observed.

## **6. Pharmaceutical particulars**

### **6.1 List of excipients**

Butylated Hydroxyanisole BP

Butylated Hydroxytoluene BP

Arachis Oil BP

### **6.2 Incompatibilities**

None

### **6.3 Shelf life**

24 months (2 Years) from date of manufacturing

### **6.4 Special precautions for storage**

Store below 30°C in a dry place. Keep medicines out of reach of children.

### **6.5 Nature and contents of container**

JASETHER 225 MG INJECTION is available in 3 ml amber colour glass ampoule with ceramic printing having OPC dot. A PVC tray having 3 such ampoules to be placed in printed carton along with pack insert.

### **6.6 Special precautions for disposal:**

None

---

**PRODUCT : JASETHER 225 MG INJECTION**

**( $\alpha$  –  $\beta$  Arteether Injection 225 mg/3 ml)**

**MODULE I : ADMINISTRATIVE INFORMATION**

**COUNTRY : NIGERIA**





**CORAL LABORATORIES LTD**

ISO 9001:2008 Certificate No. IN015692

**7. Registrant:**

**JAGSOL HEALTHCARE NIG. LTD**

**Unit 11-13, Pentcity Estate Mall, Pencity,**

**Lokogoma, District Abuja- FCT,**

**Nigeria**

**8. MANUFACTURER**

**CORAL LABORATORIES LTD.**

**Plot No.136, Village Neharoli**

**Tal-Wada, Dist-Thane 421312,**

**India.**

**9. Date of revision of the text: NA**

---

**PRODUCT : JASETHER 225 MG INJECTION**

**( $\alpha$  –  $\beta$  Arteether Injection 225 mg/3 ml)**

**MODULE I : ADMINISTRATIVE INFORMATION**

**COUNTRY : NIGERIA**

